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Introduction
The use of diabetes risk prediction tools is advocated to identify high-risk individuals who should be screened more frequently for the development of diabetes or who may benefit from intensive diabetes prevention strategies [1] [2] [3] . The available risk calculators and outcome prediction tables use a given set of risk factors to model the likelihood of developing diabetes over a defined follow-up period. There is little consensus as to which risk prediction tool is most appropriate, and most have limited applicability due to the small size or limited ethnic variability in the populations from which they were derived.
With the rising global incidence of diabetes, there is interest in improving the performance of risk prediction tools, at both an individual and a population health level. Some have sought to improve prediction by adding additional genetic [4] , laboratory [5, 6] , or clinical [7] parameters to the traditional sociodemographic risk factors of ethnicity, family history of diabetes, personal history of gestational diabetes, and physical inactivity. Comparatively little is known about the impact of change in common risk factors over time on risk prediction [8] . Using data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study (ClinicalTrials.gov NCT00097786), we investigated the incremental benefit to diabetes risk prediction of updating risk factors after 1 year of follow up [9] [10] [11] .
Materials and Methods
The NAVIGATOR study design and results have been previously published [9] [10] [11] . Briefly, 9306 participants with impaired glucose tolerance (IGT) and cardiovascular disease or cardiovascular risk factors were enrolled from 40 countries between January 2002 through factorial design; all participants received a study-specific lifestyle modification program. After randomization, fasting plasma glucose was measured every 6 months for 3 years and annually thereafter. Oral glucose tolerance tests (OGTTs) were performed annually. HbA1c was measured only at baseline. Progression to diabetes occurred if the participant had a fasting plasma glucose level ≥126 mg/dL (≥7.0 mmol/L) or ≥200 mg/dL (≥11.1 mmol/L) 2 hours after a glucose challenge, confirmed by OGTT within the following 12 weeks. The date of diabetes onset was the date of the first elevated glucose value. Among 183 patients, diabetes was diagnosed outside of the study but confirmed by an independent adjudication committee. Subjects were followed for a median of 5 years for the incidence of diabetes.
A model using baseline characteristics to predict 5-year incident diabetes has been previously published [12] . Here, we compared the performance of the baseline model to a Cox proportional hazards regression model whose inputs included information obtained after 1 year of trial follow-up (referred to as updated values). This model (hereafter referred to as the landmark model) predicts 4-year incident diabetes among patients who survived to 1 year without developing diabetes. The selection of predictors followed that used for creation of the baseline model: 10 baseline variables were forced into the model, selected according to clinical judgment rather than statistical significance (age, sex, race, body mass index [BMI] , systolic blood pressure, family history of diabetes, history of cardiovascular disease, fasting glucose, 2-hour glucose, and HbA1c). Subsequently, candidate variables were added by forward selection with a P-value of <0.05. Where updated risk factor measurements (collected at 1 year) were available, they replaced the baseline variables. Updated measurements were available for history of cardiovascular events, BMI, systolic blood pressure, fasting and 2-hr glucose levels, and platelet count. Updated risk factor measurements were not available for time constant covariates (e.g., race, region), HbA1c, LDL, or HDL. In addition, wherever both baseline and 1-year risk factor measurements were available, the change from baseline to 1 year (calculated as the baseline value minus the 1-year value) was a candidate variable. Because the baseline model was developed in a different population, possibly hindering its performance relative to the landmark model, we also refitted the baseline model covariates to the 1-year follow-up population, resulting in a model that used only baseline data but was calibrated to the population of interest. For a sensitivity analysis, we repeated the comparisons using this alternative baseline model. The competing risk of death was handled by modeling the cause-specific hazard of diabetes progression, with censoring at the time of death. This methodology mirrors that used for analyzing the diabetes endpoint for the primary trial.
As previously reported, less than 3% of data were missing for baseline covariates except HbA1c, which had 15% missing [12] . For the 1-year updated values, the highest missing rate was 10% for platelet count. The missing data were handled by multiple imputation, and the final model results, standard errors, C-indices, and predicted probabilities reflect the combined results from five imputed data sets. Baseline and landmark models were compared according to the Cindex, which is a measure of a model's ability to discriminate risk ranging from 0.5 (poor) to 1 (perfect) [13] . Model calibration was assessed graphically with observed event rates plotted against predicted event rates over deciles of predicted risk.
As a second comparison of model performance, risk classification tables were created to compare the baseline and landmark models for predicting transition to diabetes. Participants were classified by risk of progression to diabetes: modest risk (0-5%/year or 0-20% 4-year risk), moderate risk (>5-10%/year or >20-40% 4-year risk), or high risk (>10%/year or >40% 4-year risk). This clinically motivated classification paradigm is identical to that previously described and is based on the annual diabetes risk seen in the placebo groups of other diabetes prevention studies [9] . Risk reclassification tables show the differences in classification, when compared to observed Kaplan-Meier event rates. Net reclassification index (NRI) and the integrated discrimination index (IDI) are also reported, using methods for censored data [14, 15] .
SAS statistical software (Version 9.2, SAS Institute, Cary, NC, USA) was used for all statistical analyses.
Results
The population for this analysis included 7527 participants who did not die, convert to diabetes, or drop out of the study before the 1-year landmark time point (Table 1) BMI made significant contributions to the model, but change in systolic blood pressure, the history of cardiovascular disease, platelet count, and hemoglobin did not. Table 3 compares the predicted 4-year incident diabetes risk for each model with the observed risk from Kaplan-Meier probability estimates. The landmark model consistently predicts observed event rates more accurately than the baseline model, with the exception of 77 (1.0%) participants predicted to be of modest risk when the actual risk was moderate (predicted risk <20%, observed risk 24%). The corresponding NRI was 0.14 (95% CI 0.10-0. 16 
Discussion
We have demonstrated that updating risk factor values for a few key variables improves risk prediction for incident diabetes. These key variables are typically available in routine care of at risk patients: BMI, systolic blood pressure, measures of glucose, and hemoglobin. The change over 1-year follow-up in fasting and 2-hour blood glucose and BMI is also important. Based on hazard ratios and chi-square values in Table 2 , the absolute level of blood glucose (fasting or 2-hour values) is a stronger predictor of progression to diabetes than changes in glucose, but the change in BMI has a greater impact on risk prediction than the absolute level. This may imply that greater emphasis should be placed on large weight changes rather than absolute weight values when considering diabetes risk. The interim occurrence of cardiovascular events or change in systolic blood pressure does not impact prediction for diabetes.
Baseline variables shown here to be significantly associated with diabetes prediction are largely consistent with those in other predictive models. Increasing age and HDL-cholesterol levels predict decreased risk of incident diabetes, while family history of type 2 diabetes and increasing HbA1c are associated with increased diabetes risk. Of interest is our finding that higher baseline LDL-cholesterol levels are associated with a reduced risk for 4-year incident diabetes as other diabetes risk models have not identified LDL-cholesterol as an independent predictor of diabetes [3, 6, 16] . Associations between LDL-cholesterol subfractions, e.g., lipoprotein (a), and risk for diabetes have been inconsistent [17, 18] . However, lipid lowering with statin medications has been associated with increased diabetes risk in both epidemiological studies [19] [20] [21] [22] and meta-analyses of prospective clinical trials [23] [24] [25] . Whether these findings and ours indicate a possible direct link with LDL-cholesterol or whether there is confounding as a result of statin therapy deserves further consideration.
Examination of the chi-square values demonstrates that glucose measures are the strongest predictors of progression, in both baseline and landmark models. The next largest chisquare values are seen for the change in fasting and 2-hour glucose. Closer examination appears to show a counterintuitive result: an increased hazard if glucose values decrease from baseline to 1 year. To understand this apparent paradox, it is important to remember that when change variables are added to the model, the effects are interpreted holding all other covariates (e.g., the absolute glucose value) constant (Figure 1 ). Among two people with equivalent 1-year fasting glucose, the individual whose glucose decreases over 1 year of follow-up had a higher glucose, on average, than a person who increases to the same point. Therefore, a person with higher average glucose is more likely to progress to diabetes than a person with lower average glucose.
Our results suggest that the change in glucose values is important, in that it captures information about previous levels.
The reclassification table demonstrates the incremental benefit of updating risk calculations. In every case of discrepancy between the models, the observed event rates were consistent with the landmark model classification but not the baseline model classification. A striking example is the 481 patients classified as moderate risk (20-40%) by the baseline model but high risk (>40%) by the landmark model. The observed 4-year event rate in these patients was 59%. If applied across a population health setting, this degree of misclassification could result in highly inaccurate estimates of the cost and effort required for diabetes prevention interventions to be effective.
There are important limitations to these findings. First, the NAVIGATOR population was constrained at entry by baseline glucose values. To be eligible, participants were required to have either IGT or fasting plasma glucose of at least 95 mg/dL (5.3 mmol/L) but <126 mg/dL (7.0 mmol/L). Therefore, our models are only generalizable to populations first identified to have elevated fasting glucose or IGT and then followed forward for 1 year. This is a particularly important limitation given the strength of the fasting and 2-hour glucose levels as predictors in both the baseline and landmark models. By definition, there is a wider distribution of glucose values in the population at the 1-year time point, potentially contributing to the improved discrimination seen in the landmark model. Another limitation is that, due to the study design, updated 1-year values were not available for all variables (e.g., LDL, HDL), but it seems unlikely that the impact of these variables would outweigh that seen for the glucose variables.
Lifestyle modification [26, 27] and metformin treatment [26] have proven efficacy for diabetes prevention. However, patients often find it difficult to implement and maintain the changes in diet and exercise required to reap the benefits. Furthermore, although recommended by the American Diabetes Association and other international guidelines [28] , metformin is not formally approved for diabetes prevention, causing some payers not to reimburse its use for patients with IGT. These barriers, combined with poor uptake of screening for diabetes in many health care systems, decrease the ability to cope with the growing incidence of diabetes worldwide. Diabetes prediction tools could help to better target individuals at highest risk of conversion to diabetes for receipt of diabetes prevention interventions. However, our findings demonstrate that using historical data to inform diabetes risk calculations may underestimate the true magnitude of the problem. In a cohort with IGT followed in clinical practice, diabetes risk calculations should be routinely updated to inform discussions about diabetes prevention at both the patient and population health levels. Change values in the model are interpreted holding all other variables constant. Therefore, among two individuals with an equivalent 1-year fasting plasma glucose (FPG), Individual A, whose fasting glucose decreases over time, had a higher baseline glucose value than an individual whose glucose increases to the same point. Therefore, Individual A carries a higher overall risk for developing diabetes. The change value captures information about the absolute change in glucose level and some information about the baseline value as well.
